How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

13,776 results for

Ages and Stages Questionnaire

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

201. Use of the Young Schema Questionnaire - Short Form Version 3 (YSQ-S3) in the evaluation of populations with mental and personality disorders: a systematic review

Use of the Young Schema Questionnaire - Short Form Version 3 (YSQ-S3) in the evaluation of populations with mental and personality disorders: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content (...) graphs using digital ruler software. In case data are not reported or unclear, we will attempt to contact authors by e-mail (max. 2 attempts). In case an outcome is measured at multiple time points, data from the time point where efficacy is highest will be included. ">Methods for data extraction Example: Experimental groups, control group(s) and number of animals per group. ">Data to be extracted: study design Example: Species, sex, weight, age, co‐morbidity, anaesthetic agent used, method

2020 PROSPERO

202. Environmental stressors questionnaires in intensive care units.

Environmental stressors questionnaires in intensive care units. Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g (...) will attempt to contact authors by e-mail (max. 2 attempts). In case an outcome is measured at multiple time points, data from the time point where efficacy is highest will be included. ">Methods for data extraction Example: Experimental groups, control group(s) and number of animals per group. ">Data to be extracted: study design Example: Species, sex, weight, age, co‐morbidity, anaesthetic agent used, method of induction of cardiac ischemia, duration of ischemia and duration of reperfusion (if applicable

2020 PROSPERO

203. Effects of physical activity measurement by questionnaire and/or accelerometry in adolescents: systematic review of observational studies

Effects of physical activity measurement by questionnaire and/or accelerometry in adolescents: systematic review of observational studies Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration (...) ruler software. In case data are not reported or unclear, we will attempt to contact authors by e-mail (max. 2 attempts). In case an outcome is measured at multiple time points, data from the time point where efficacy is highest will be included. ">Methods for data extraction Example: Experimental groups, control group(s) and number of animals per group. ">Data to be extracted: study design Example: Species, sex, weight, age, co‐morbidity, anaesthetic agent used, method of induction of cardiac

2020 PROSPERO

204. World wide common chronic diseases compared with the EQ-5D questionnaire concerning quality of life.

World wide common chronic diseases compared with the EQ-5D questionnaire concerning quality of life. Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files (...) are not reported or unclear, we will attempt to contact authors by e-mail (max. 2 attempts). In case an outcome is measured at multiple time points, data from the time point where efficacy is highest will be included. ">Methods for data extraction Example: Experimental groups, control group(s) and number of animals per group. ">Data to be extracted: study design Example: Species, sex, weight, age, co‐morbidity, anaesthetic agent used, method of induction of cardiac ischemia, duration of ischemia and duration

2020 PROSPERO

205. Application of questionnaires on the quality of life of elderly individuals with tinnitus: a systematic review and meta-analysis.

Application of questionnaires on the quality of life of elderly individuals with tinnitus: a systematic review and meta-analysis. Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record (...) ruler software. In case data are not reported or unclear, we will attempt to contact authors by e-mail (max. 2 attempts). In case an outcome is measured at multiple time points, data from the time point where efficacy is highest will be included. ">Methods for data extraction Example: Experimental groups, control group(s) and number of animals per group. ">Data to be extracted: study design Example: Species, sex, weight, age, co‐morbidity, anaesthetic agent used, method of induction of cardiac

2020 PROSPERO

206. Associations of preoperative STOP-Bang questionnaire scores with adverse cardiovascular events in patients undergoing noncardiac surgery: A systematic review and meta-analysis

Associations of preoperative STOP-Bang questionnaire scores with adverse cardiovascular events in patients undergoing noncardiac surgery: A systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability (...) will extract data from graphs using digital ruler software. In case data are not reported or unclear, we will attempt to contact authors by e-mail (max. 2 attempts). In case an outcome is measured at multiple time points, data from the time point where efficacy is highest will be included. ">Methods for data extraction Example: Experimental groups, control group(s) and number of animals per group. ">Data to be extracted: study design Example: Species, sex, weight, age, co‐morbidity, anaesthetic agent used

2020 PROSPERO

207. Child Eating Behavior Questionnaire (CEBQ) to diagnose the eating behavior of overweight and obese children and adolescents: A systematic review.

Child Eating Behavior Questionnaire (CEBQ) to diagnose the eating behavior of overweight and obese children and adolescents: A systematic review. Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content (...) graphs using digital ruler software. In case data are not reported or unclear, we will attempt to contact authors by e-mail (max. 2 attempts). In case an outcome is measured at multiple time points, data from the time point where efficacy is highest will be included. ">Methods for data extraction Example: Experimental groups, control group(s) and number of animals per group. ">Data to be extracted: study design Example: Species, sex, weight, age, co‐morbidity, anaesthetic agent used, method

2020 PROSPERO

208. Protocol for a systematic review of patient reported outcome measures (PROMs) to inform item development for a new questionnaire of listening effort in cochlear implantation - the Listening Effort Questionnaire (LEQ)

Protocol for a systematic review of patient reported outcome measures (PROMs) to inform item development for a new questionnaire of listening effort in cochlear implantation - the Listening Effort Questionnaire (LEQ) Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated (...) are not reported or unclear, we will attempt to contact authors by e-mail (max. 2 attempts). In case an outcome is measured at multiple time points, data from the time point where efficacy is highest will be included. ">Methods for data extraction Example: Experimental groups, control group(s) and number of animals per group. ">Data to be extracted: study design Example: Species, sex, weight, age, co‐morbidity, anaesthetic agent used, method of induction of cardiac ischemia, duration of ischemia and duration

2017 PROSPERO

209. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults

2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines | Hypertension Search Hello Guest! Login to your account Email Password (...) Keep me logged in Search April 2019 March 2019 February 2019 January 2019 This site uses cookies. By continuing to browse this site you are agreeing to our use of cookies. Free Access article Share on Jump to Free Access article 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

2017 American Heart Association

210. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary Full Text available with Trip Pro

2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines | Hypertension Search Hello Guest (...) ! Login to your account Email Password Keep me logged in Search April 2019 March 2019 February 2019 January 2019 This site uses cookies. By continuing to browse this site you are agreeing to our use of cookies. Free Access article Share on Jump to Free Access article 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart

2017 American Heart Association

211. Interventions to Prevent Age-Related Cognitive Decline, Mild Cognitive Impairment, and Clinical Alzheimer's-Type Dementia

Interventions to Prevent Age-Related Cognitive Decline, Mild Cognitive Impairment, and Clinical Alzheimer's-Type Dementia Comparative Effectiveness Review Number 188 Interventions To Prevent Age-Related Cognitive Decline, Mild Cognitive Impairment, and Clinical Alzheimer’s-Type Dementia eComparative Effectiveness Review Number 188 Interventions To Prevent Age-Related Cognitive Decline, Mild Cognitive Impairment, and Clinical Alzheimer’s-Type Dementia Prepared for: Agency for Healthcare Research (...) @ahrq.hhs.gov. Suggested citation: Kane RL, Butler M, Fink HA, Brasure M, Davila H, Desai P, Jutkowitz E, McCreedy E, Nelson VA, McCarten JR, Calvert C, Ratner E, Hemmy LS, Barclay T. Interventions To Prevent Age-Related Cognitive Decline, Mild Cognitive Impairment, and Clinical Alzheimer’s-Type Dementia. Comparative Effectiveness Review No. 188. (Prepared by the Minnesota Evidence-based Practice Center under Contract No. 290-2015-00008-I.) AHRQ Publication No. 17-EHC008-EF. Rockville, MD: Agency

2017 Effective Health Care Program (AHRQ)

212. Interventions to Prevent Age-Related Cognitive Decline, Mild Cognitive Impairment, and Clinical Alzheimer's-Type Dementia

Interventions to Prevent Age-Related Cognitive Decline, Mild Cognitive Impairment, and Clinical Alzheimer's-Type Dementia Comparative Effectiveness Review Number 188 Interventions To Prevent Age-Related Cognitive Decline, Mild Cognitive Impairment, and Clinical Alzheimer’s-Type Dementia eComparative Effectiveness Review Number 188 Interventions To Prevent Age-Related Cognitive Decline, Mild Cognitive Impairment, and Clinical Alzheimer’s-Type Dementia Prepared for: Agency for Healthcare Research (...) @ahrq.hhs.gov. Suggested citation: Kane RL, Butler M, Fink HA, Brasure M, Davila H, Desai P, Jutkowitz E, McCreedy E, Nelson VA, McCarten JR, Calvert C, Ratner E, Hemmy LS, Barclay T. Interventions To Prevent Age-Related Cognitive Decline, Mild Cognitive Impairment, and Clinical Alzheimer’s-Type Dementia. Comparative Effectiveness Review No. 188. (Prepared by the Minnesota Evidence-based Practice Center under Contract No. 290-2015-00008-I.) AHRQ Publication No. 17-EHC008-EF. Rockville, MD: Agency

2017 Effective Health Care Program (AHRQ)

213. Clinical experiences with the use of ULTRAPRO<sup>®</sup> mesh in single-stage direct-to-implant immediate postmastectomy breast reconstruction in 102 patients: A retrospective cohort study. (Abstract)

as a low-cost potential alternative to biological matrices.A retrospective cohort study was performed between January 2013 and January 2016, involved 112 early-stage breast cancer and/or BRCA 1/2 patients, and evaluated 189 immediate DTI BRs following skin-, areola- or nipple-sparing mastectomy using ULTRAPRO® mesh. Patient characteristics and postoperative complications were recorded, and quality of life was rated by the patients using the EORTC-QLQ-C30-BR23 questionnaire. Aesthetic outcomes (...) Clinical experiences with the use of ULTRAPRO® mesh in single-stage direct-to-implant immediate postmastectomy breast reconstruction in 102 patients: A retrospective cohort study. Acellular dermal matrices have been used for direct-to-implant (DTI) breast reconstruction (BR), eliminating the load of the lower pole skin envelope. However, the available allograft matrices add considerable health care costs. This study examined the long-term follow-up of synthetic ULTRAPRO® mesh

2017 European Journal of Surgical Oncology

214. SOX Versus XELOX as Adjuvant Chemotherapy for Stage III Colorectal Cancer Patients

SOX Versus XELOX as Adjuvant Chemotherapy for Stage III Colorectal Cancer Patients SOX Versus XELOX as Adjuvant Chemotherapy for Stage III Colorectal Cancer Patients - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before (...) adding more. SOX Versus XELOX as Adjuvant Chemotherapy for Stage III Colorectal Cancer Patients The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03448549 Recruitment Status : Recruiting First Posted : February 28, 2018 Last

2017 Clinical Trials

215. Design of an Integrative Algorithm for Staging Tuberculosis

Design of an Integrative Algorithm for Staging Tuberculosis Design of an Integrative Algorithm for Staging Tuberculosis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Design of an Integrative Algorithm (...) for Staging Tuberculosis (STAGE-TB) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03691883 Recruitment Status : Recruiting First Posted : October 2, 2018 Last Update Posted : October 10, 2018 See Sponsor: Fundació Institut

2017 Clinical Trials

216. Gazyvaro and Low Dose Radiotherapy in Early Stage Follicular Lymphoma

See Sponsor: Heidelberg University Collaborator: Roche Pharma AG Information provided by (Responsible Party): Klaus Herfarth, MD, Heidelberg University Study Details Study Description Go to Brief Summary: Combined modality approach using Obitunuzumab and involved site low dose irradiation in early stage nodal follicular lymphoma. Radiation dose will be adapted for low-responders. Primary Objective: Evaluation of the rate of metabolic CR after low-dose involved site radiotherapy in combination (...) - or immunotherapy) nodal lymphoma (including involvement of Waldeyer´s ring) Age: ≥18 years ECOG: 0-2 Stage: clinical stage I or II (Ann Arbor classification) Risk profile: Largest diameter of the lymphoma * 7 cm (sectional images) Written informed consent and willingness to cooperate during the course of the trial Adequate hematologic function (unless abnormalities are related to NHL), defined as follows: Hemoglobin ≥ 9.0 g/dL; absolute neutrophil count ≥ 1.5 × 109/L, Platelet count ≥ 75 × 109/L Capability

2017 Clinical Trials

217. PG2 Treatment Among Stage II/III Breast Cancer Patients Receiving Adjuvant Chemotherapy

Eligibility: Yes Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Women who are able to provide informed consent Age 20 years and older Diagnosis of stage II to III breast cancer Patients who had undergone surgery for breast cancer treatment. Planning to receive anthracycline -based adjuvant chemotherapy Have adequate bone marrow, liver, and renal function ECOG ≦1 Willing and able to complete quality of life questionnaires. Exclusion Criteria: Pregnancy or lactating women. Baseline BFI score >3 (...) PG2 Treatment Among Stage II/III Breast Cancer Patients Receiving Adjuvant Chemotherapy PG2 Treatment Among Stage II/III Breast Cancer Patients Receiving Adjuvant Chemotherapy - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies

2017 Clinical Trials

218. Feasibility and Acceptability of Implementing a Clinic-based Physical Activity Coaching Intervention in People With Premanifest and Early Stage HD

in Unified Huntington Disease rating scale Total Motor Score at 4 months [ Time Frame: 4 months ] Disease-specific measure of motor function Change in Behavioral Regulation in Exercise Questionnaire (BREQ 2) at 4 months [ Time Frame: 4 months ] A 19 item questionnaire measuring stages of self determination continuum Change in Unified Huntington Disease Rating Scale Cognitive battery at 4 months [ Time Frame: 4 months ] Disease-specific cognitive function as measured by Unified Huntington Disease (...) Questionnaire (PAR-Q), or medical clearance from General Practioner For potential participants over age 60, a minimum score of 24 on the Mini-Mental State Examination (MMSE) (completed within 3 months) will be required for capacity to consent. For potential participants age 60-65, successful pass of electrocardiogram screen will be required. Exclusion Criteria: Musculoskeletal injury that would interfere with participation in an exercise program Currently participating in a structured exercise program 3

2017 Clinical Trials

219. Home-based Computerized Cognitive Rehabilitation in Chronic Stage Stroke

Home-based Computerized Cognitive Rehabilitation in Chronic Stage Stroke Home-based Computerized Cognitive Rehabilitation in Chronic Stage Stroke - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Home-based (...) Computerized Cognitive Rehabilitation in Chronic Stage Stroke (CHRONIC) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03326349 Recruitment Status : Recruiting First Posted : October 31, 2017 Last Update Posted : November 1

2017 Clinical Trials

220. Sensitivity of Preference-Based Quality-of-Life Measures for Economic Evaluations in Early-Stage Melanoma. Full Text available with Trip Pro

participants' HRQOL, demographic, and clinical characteristics using the χ2 test and F statistic. Both the FACT-M and AQoL-8D utilities were regressed on FCR Inventory (FCRI) severity scores to estimate the effect of elevated FCR on HRQOL.A total of 164 participants completed the baseline questionnaires, but only 163 met all inclusion criteria and underwent the full analysis: 72 were women; 91 were men; and mean (SD) age was 58.2 (12.1) years. Both the AQoL-8D and FACT-M instruments showed good concurrent (...) Sensitivity of Preference-Based Quality-of-Life Measures for Economic Evaluations in Early-Stage Melanoma. The diagnosis of a life-threatening disease like melanoma can affect all aspects of a person's life, including health-related quality of life (HRQOL) and psychological aspects of melanoma such as fear of cancer recurrence (FCR). Economic evaluations of psychological interventions require preference-based (utility) instruments that are sensitive to changes in well-being and HRQOL; however

2017 JAMA dermatology (Chicago, Ill.) Controlled trial quality: uncertain

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>